← Back to Screener
PolyPid Ltd. Ordinary Shares (PYPD)
Price$5.07
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)14.10%
Price vs S&P 500 (4W)1.33%
VGM Score66.65
Market Capitalization$90.07M
All Metrics
Book Value / Share (Quarterly)$0.46
P/TBV (Annual)1.12x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.54
Price vs S&P 500 (YTD)-2.18%
EPS (TTM)$-1.91
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-1.91
EPS (Annual)$-2.09
ROI (Annual)-285.67%
Cash / Share (Quarterly)$0.57
ROA (Last FY)-153.18%
EBITD / Share (TTM)$-0.34
ROE (5Y Avg)-307.35%
Cash Flow / Share (Annual)$-1.54
P/B Ratio10.26x
P/B Ratio (Quarterly)9.52x
Net Income / Employee (Annual)$-495,200
Net Interest Coverage (TTM)40.47x
ROA (TTM)-126.91%
EPS Incl Extra (Annual)$-2.09
Current Ratio (Annual)1.97x
Quick Ratio (Quarterly)1.58x
3-Month Avg Trading Volume0.07M
52-Week Price Return69.18%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.14
52-Week High$5.20
EPS Excl Extra (Annual)$-2.09
CapEx CAGR (5Y)-23.08%
26-Week Price Return30.03%
Quick Ratio (Annual)1.77x
13-Week Price Return11.85%
Total Debt / Equity (Annual)0.09x
Current Ratio (Quarterly)1.78x
Enterprise Value$81.99M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.71
3-Month Return Std Dev43.68%
Net Income / Employee (TTM)$-487,400
ROE (Last FY)-311.39%
Net Interest Coverage (Annual)-20.86x
EPS Basic Excl Extra (Annual)$-2.09
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$-1.91
ROI (TTM)-202.75%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.81
Price vs S&P 500 (52W)40.97%
Year-to-Date Return8.76%
5-Day Price Return-5.98%
EPS Normalized (Annual)$-2.09
ROA (5Y Avg)-134.43%
Month-to-Date Return4.89%
EBITD / Share (Annual)$-1.96
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-174.78%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.91
P/TBV (Quarterly)1.85x
P/B Ratio (Annual)6.29x
Book Value / Share (Annual)$0.60
Price vs S&P 500 (13W)2.10%
Beta1.46x
Revenue / Share (TTM)$0.00
ROE (TTM)-241.96%
52-Week Low$2.44
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.35est. -0.44
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.10
4.10
4.10
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PYPDPolyPid Ltd. Ordinary Shares | — | — | B | $5.07 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
PolyPid Ltd is a clinical-stage biopharmaceutical company developing therapies based on PLEX, its proprietary drug delivery technology that enables targeted, localized drug release over extended periods. The company's lead candidate, D-PLEX100, is being developed to prevent surgical site infections, while OncoPLEX represents a potential intra-tumoral cancer treatment platform.